Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs – many are finding ways around it

A survey found 36% of employers now provide GLP-1 coverage for both diabetes and weight loss—flat versus 2025 but up from 34% in 2024—suggesting continued employer support for these drugs. The change is modest and likely more indicative of steady demand than a near-term earnings shock.

Analysis

A survey found 36% of employers now provide GLP-1 coverage for both diabetes and weight loss—flat versus 2025 but up from 34% in 2024—suggesting continued employer support for these drugs. The change is modest and likely more indicative of steady demand than a near-term earnings shock.